Residency · Residency · Chronic Pain Management
Opioid Risk Stratification and Monitoring
Introduction
Effective risk stratification and ongoing monitoring are essential components of responsible opioid prescribing for chronic pain. Given the approximately 8-12% incidence of opioid use disorder among chronic pain patients prescribed opioids, clinicians must systematically assess risk before initiating therapy, employ validated screening tools, interpret urine drug testing accurately, utilize prescription drug monitoring programs (PDMPs), and identify aberrant behaviors that may indicate misuse, diversion, or developing addiction. This lecture provides a practical framework for each of these critical competencies.
Risk Assessment Tools
Opioid Risk Tool (ORT)
The ORT is a brief, self-administered 5-item screening tool that can be completed in under one minute. It assesses personal and family history of substance abuse, age, history of preadolescent sexual abuse, and psychological disease. Scoring categorizes patients as low risk (0-3), moderate risk (4-7), or high risk (8 or above). Separate scoring weights exist for male and female versions.
The ORT's strengths are its speed, simplicity, and face validity. Its limitations are significant, however: it relies on patient self-report and is easily manipulated, its validation is primarily from a single study population, and it has poor sensitivity for moderate-risk patients. It is best used as an initial screening tool at the point of opioid consideration, not as a definitive risk assessment.
Screener and Opioid Assessment for Patients with Pain -- Revised (SOAPP-R)
The SOAPP-R is a 24-item self-administered questionnaire requiring approximately 10 minutes. It assesses emotional and behavioral patterns predictive of aberrant opioid use, with items covering need for medications, mood instability, social supports, history of legal problems, boredom, and impulsivity. A score of 18 or above indicates high risk for opioid misuse.
The SOAPP-R has better psychometric properties than the ORT, is validated in diverse populations, and includes items resistant to deception. Its sensitivity is approximately 73% and specificity approximately 62% for predicting aberrant behavior. The main limitations are longer administration time and the possibility that patients may minimize their history.
Diagnosis, Intractability, Risk, Efficacy (DIRE) Score
The DIRE score is a clinician-rated tool — not self-administered — based on provider assessment across four domains. The Diagnosis domain rates the objectivity of the pain condition. The Intractability domain rates prior treatment attempts. The Risk domain encompasses psychological, chemical, reliability, and social support subscales. The Efficacy domain rates the expected benefit of opioid therapy. Each domain is scored on a 1-3 scale, yielding a total score of 7-21, with scores of 14 or above suggesting a suitable candidate for chronic opioid therapy.
The DIRE's strengths include reduced self-report bias and the assessment of positive prognostic factors, not just risk. Its limitations include subjectivity, limited validation data, and greater time intensity.
Comparative Considerations
| Tool | Items | Administration | Time | Risk Categories | Sensitivity | Specificity |
|---|---|---|---|---|---|---|
| ORT | 5 | Self-report | <1 min | Low (0–3), Moderate (4–7), High (≥8) | Moderate | Moderate |
| SOAPP-R | 24 | Self-report | ~10 min | High risk ≥18 | 73% | 62% |
| DIRE | 4 domains | Clinician-rated | 5–10 min | Suitable ≥14 (score 7–21) | — | — |
| COMM | 17 | Self-report | ~5 min | Misuse concern ≥9 | 77% | 66% |
No single tool is sufficient for risk assessment — screening tools should be combined with clinical judgment. Risk assessment should be repeated periodically, not just performed at initiation. All tools have moderate sensitivity and specificity, supplementing but not replacing clinical reasoning. Pharmacogenomic testing (CYP2D6 status) can serve as an adjunctive risk factor assessment.
<image>Side-by-side comparison chart of the three major opioid risk assessment tools (ORT, SOAPP-R, DIRE), each displayed as a card with sections showing: number of items, administration method (self-report vs clinician-rated), time to complete, scoring thresholds with risk categories, sensitivity and specificity values, key domains assessed as icons, and a strengths/limitations summary, with a recommendation bar at the bottom indicating when in the clinical workflow each tool is most appropriately used</image>
Urine Drug Testing (UDT) Interpretation
Immunoassay Screening (Point-of-Care)
Initial screening uses immunoassay technology with threshold-based positive/negative results. Standard panels detect opiates, benzodiazepines, cocaine metabolites, amphetamines, THC, PCP, and sometimes methadone. The critical limitations must be understood. The "opiates" assay detects morphine, codeine, and heroin metabolites but does not reliably detect oxycodone, oxymorphone, fentanyl, methadone, buprenorphine, or tramadol — synthetic and semi-synthetic opioids require specific immunoassays or confirmatory testing. False positives are common: poppy seeds can trigger a positive morphine/codeine result, quinolones can cause false-positive amphetamines, sertraline can cause false-positive benzodiazepines, dextromethorphan can trigger false-positive PCP, and efavirenz can cause false-positive THC. False negatives occur with dilute specimens, adulterated samples, or drugs not included in the panel.
Confirmatory Testing (LC-MS/MS)
Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the gold standard for definitive identification. It identifies specific drug metabolites, quantifies concentrations, and can differentiate between related opioids and their metabolites (for example, distinguishing morphine from hydromorphone). Confirmatory testing is essential for medicolegal decisions and for resolving unexpected screening results. It is more expensive but eliminates false positive and false negative issues.
Interpretation Pearls
Understanding expected metabolites is critical for accurate interpretation. Codeine metabolizes to morphine (and a small amount of hydrocodone). Hydrocodone metabolizes to hydromorphone (and norhydrocodone). Oxycodone metabolizes to oxymorphone (and noroxycodone). Heroin metabolizes to 6-monoacetylmorphine (6-MAM), then to morphine.
The absence of a prescribed opioid may indicate non-adherence, diversion, or simply that the last dose was taken too long before specimen collection. When a non-prescribed substance appears, the clinician must differentiate between undisclosed use and metabolic conversions — hydromorphone in a patient prescribed hydrocodone is an expected metabolite, not evidence of non-prescribed use.
Specimen validity testing is essential: creatinine below 20 mg/dL suggests dilution, below 2 mg/dL suggests substitution. Temperature, specific gravity, and pH should also be checked.
<image>Opioid metabolism reference chart formatted as a clinical pocket guide showing metabolic conversion pathways relevant to UDT interpretation, with arrows connecting parent drugs to their metabolites: codeine to morphine and hydrocodone, hydrocodone to hydromorphone, oxycodone to oxymorphone, heroin to 6-MAM to morphine, with color coding to distinguish expected metabolites (green) from unexpected findings that warrant investigation (red), and a specimen validity testing checklist in the margin</image>
Prescription Drug Monitoring Programs (PDMPs)
Overview
PDMPs are state-operated electronic databases that track controlled substance dispensing. All 50 US states plus DC and US territories have operational PDMPs, and most states mandate prescriber review before initiating opioids and at regular intervals during therapy. Data captured includes patient name, drug dispensed, quantity, days' supply, prescriber, pharmacy, and date filled.
Clinical Utility
PDMPs identify patients receiving multiple concurrent opioid prescriptions from different providers ("doctor shopping"), detect dangerous combinations such as concurrent opioids and benzodiazepines, reveal escalating patterns of controlled substance use, and allow verification of patient-reported prescription history. They should be used as a clinical tool for patient safety, not as a punitive surveillance mechanism.
PDMP Best Practices
The PDMP should be checked before initiating opioid therapy and at every prescription renewal. Reviews should look for recent dispensing activity, overlapping prescriptions, multiple prescribers, and cash payments. Neighboring state PDMPs should be checked when applicable, as many states participate in interstate data sharing via PMPInterConnect. PDMP review should be documented in the medical record. When concerning findings are identified, they should be addressed directly with the patient — the appropriate response is a conversation, not a unilateral refusal of care. PDMP data should be one component of comprehensive risk assessment, never used in isolation.
Limitations
Data entry lag times vary from real-time to two weeks depending on the state. PDMPs do not capture illicit drug use, veterinary prescriptions, or VA/military prescriptions (though integration is improving). Interstate variability in reporting requirements exists. A "clean" PDMP does not rule out all problematic use.
Aberrant Behavior Identification
Spectrum of Aberrant Behaviors
Aberrant behaviors exist on a spectrum from less concerning to highly concerning, and the appropriate clinical response differs accordingly.
Less concerning behaviors that may simply indicate undertreated pain include requesting specific medications by name, occasional unsanctioned dose escalation, drug hoarding during periods of reduced pain, using opioids for sleep or anxiety (self-medication), and one-time acquisition of opioids from family members.
More concerning behaviors suggesting possible misuse or addiction include repeated unsanctioned dose escalation despite warnings, obtaining opioids from multiple prescribers simultaneously, multiple reports of lost or stolen prescriptions, resistance to medication changes or non-opioid alternatives, functional decline despite stable or increasing doses, and missing appointments while calling for refills.
Highly concerning behaviors that strongly suggest addiction or diversion include forging or altering prescriptions, selling or diverting prescribed medications, injecting oral formulations, concurrent illicit drug use (heroin, non-prescribed fentanyl, cocaine), obtaining opioids from non-medical sources, repeatedly inconsistent UDT results, and criminal activity related to obtaining drugs.
Response to Aberrant Behaviors
Aberrant behaviors should prompt reassessment, not automatic dismissal from care. The intensity of monitoring should be increased with more frequent visits, UDT, pill counts, and PDMP checks. Shorter prescription intervals (weekly dispensing) can be considered. The diagnosis should be reassessed to determine whether undertreated pain is driving the behavior. Screening for opioid use disorder using DSM-5 criteria is appropriate. If OUD is diagnosed, medication-assisted treatment (buprenorphine or methadone) should be offered rather than patient abandonment. All findings, discussions, and clinical rationale for management decisions must be documented.
<image>Clinical decision pathway for responding to aberrant opioid behaviors, structured as a flowchart starting with identification of the behavior, proceeding through severity assessment (less concerning, more concerning, highly concerning), branching to appropriate responses at each level including increased monitoring, reassessment of diagnosis and treatment plan, screening for opioid use disorder, and referral for addiction treatment, with a parallel track showing documentation requirements at each step and patient communication strategies emphasizing therapeutic alliance preservation</image>
Comprehensive Monitoring Protocol
Initial Assessment (Before Prescribing)
Before prescribing opioids, the clinician should complete a full pain evaluation with diagnosis confirmation, administer a risk assessment tool (ORT or SOAPP-R), review the PDMP, obtain a baseline UDT, conduct psychiatric screening (PHQ-9, GAD-7), establish a baseline functional assessment, and execute informed consent and a treatment agreement.
Ongoing Monitoring Schedule
During months 1-3, visits should occur every 2-4 weeks with UDT and PDMP checks at each visit. From months 3-12, stable low-risk patients can be seen every 1-3 months with UDT at least quarterly. After 12 months, visits should occur at least every 3 months with UDT at least twice yearly and a comprehensive annual reassessment. High-risk patients should maintain more frequent monitoring indefinitely.
Parameters to Assess at Each Visit
Each visit should evaluate pain intensity (NRS 0-10, though functional measures should be weighted more heavily), function using the "4 A's" framework (Analgesia, Activities of daily living, Adverse effects, Aberrant behaviors), medication adherence (with pill counts if indicated), mood and psychiatric status (screening for depression, anxiety, suicidality), PDMP review documentation, and side effects including constipation, sedation, hormonal issues, and cognitive effects.
Clinical Pearls
The ORT takes less than one minute and is suitable for initial screening, but the SOAPP-R has superior psychometric properties for identifying high-risk patients. When interpreting UDT results, always know the metabolic pathways — hydromorphone in a patient on hydrocodone is an expected metabolite, not evidence of non-prescribed use. Standard immunoassay "opiate" screens do not detect oxycodone, fentanyl, methadone, or buprenorphine — specific assays or confirmatory LC-MS/MS must be ordered. PDMP data should be used as a clinical tool for patient safety, not a punitive surveillance mechanism — frame discussions with patients around safety. Aberrant behaviors exist on a spectrum, and a single concerning behavior warrants increased monitoring and conversation, not automatic discharge from the practice. The "4 A's" (Analgesia, Activity, Adverse effects, Aberrant behavior) provide a simple framework for documenting each opioid monitoring visit.
References
- Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2005;6(6):432-442.
- Butler SF, Fernandez K, Benoit C, Budman SH, Jamison RN. Validation of the revised Screener and Opioid Assessment for Patients with Pain (SOAPP-R). J Pain. 2008;9(4):360-372.
- Moeller KE, Kissack JC, Atayee RS, Lee KC. Clinical interpretation of urine drug tests: what clinicians need to know about urine drug screens. Mayo Clin Proc. 2017;92(5):774-796.
- Dowell D, Ragan KR, Jones CM, Baldwin GT, Chou R. CDC clinical practice guideline for prescribing opioids for pain — United States, 2022. MMWR Recomm Rep. 2022;71(3):1-95.
